FDA
-
-
-
-
-
-
-
Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S.
-
-
-
-
-
-
-
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre
-
-
-
-
-
-
-
Leqembi subcutaneous data shows similar efficacy to IV in Alzheimer's
-
-
-
-
-
-
-
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
-
-
-
-
-
-
-
Biogen's diranersen shows tau reduction in Alzheimer's trial
-
-
-
-
-
-
-
Stoke Therapeutics adds Clare Kahn to board of directors
-
-
-
-
-
-
-
Biogen reports positive phase 2 results for lupus skin drug
-
330,738 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

